References
- Falk GW. Endoscopic surveillance of Barrett's esophagus: risk stratification and cancer risk. Gastrointest Endose 1999; 49(3 Pt 2): S29–34
- Reid BJ, Weinstein WM, Lewin KJ, et al. Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions. Gastroenterology 1988; 94(1): 81–90
- Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 1028–32
- Falk G. Unresolved issues in Barrett's esophagus in the new millennium. Dig Dis 2000; 18(1): 27–42
- Cameron AJ, Lomboy CT. Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology 1992; 103(4): 1241–5
- Falk GW, Chittajallu R, Goldblum JR, et al. Surveillance of patients with Barrett's esophagus for dysplasia and cancer with balloon cytology. Gastroenterology 1997; 112(6): 1787–97
- Gopal DV, Faigel DO, Magaret N, et al. Risk factors for dysplasia in patients with Barrett's esophagus (BE): results from a multicenter consortium. (Abstr) Gastroenterology 1999; 116(4 Pt 2): A175
- Katz D, Rothstein R, Schned A, et al. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. Am J Gastroenterol 1998; 93(4): 536–41
- Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999; 94(8): 2043–53
- Rudolph RE, Vaughan TL, Storer BE, et al. Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med 2000; 132(8): 612–20
- Younes M, Lebovitz RM, Lechago LV, et al. p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study. Gastroenterology 1993; 105(6): 1637–42
- Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol 1997; 92(4): 582–5
- Haag S, Nandurkar S, Talley NJ. Regression of Barrett's esophagus: the role of acid suppression, surgery, and ablative methods. Gastrointest Endosc 1999; 50(2): 229–40
- Williamson WA, Ellis FH Jr, Gibb SP, et al. Effect of antireflux operation on Barrett's mucosa. Ann Thorac Surg 1990; 49(4): 537–42
- Low DE, Levine DS, Dail DH, et al. Histological and anatomic changes in Barrett's esophagus after antireflux surgery. Am J Gastroenterol 1999; 94(1): 80–5
- Brand DL, Ylvisaker JT, Gelfand M, et al. Regression of columnar esophageal (Barrett's) epithelium after anti-reflux surgery. N Engl J Med 1980; 302(15): 844–6
- Sampliner RE, Fennerty B, Garewal HS. Reversal of Barrett's esophagus with acid suppression and multipolar electrocoagulation: preliminary results. Gastrointest Endosc 1996; 44(5): 523–5
- Byrne JP, Armstrong GR, Attwood SE. Restoration of the normal squamous lining in Barrett's esophagus by argon beam plasma coagulation. Am J Gastroenterol 1998; 93(10): 1810–5
- Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gastrointest Endosc 1999; 49(1): 1–7
- Morgan G, Vainio H. Barrett's oesophagus, oesophageal cancer and colon cancer: an explanation of the association and cancer chemopreventive potential of non-steroidal anti-inflammatory drugs. Eur J Cancer Prevent 1998; 7(3): 195–9
- Farrow DC, Vaughan TL, Hansten PD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998; 7(2): 97–102
- Wilson KT, Fu S, Ramanujam KS, et al. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998; 58(14): 2929–34